Background and Objective: In microdose studies, the pharmacokinetic profile of a drug in blood after administration of a dose up to 100 mg is measured with sensitive analytical techniques, such as accelerator mass spectrometry (AMS). As most drugs exert their effect in tissue rather than blood, methodology is needed for extending pharmacokinetic analysis to different tissue compartments. In the present study, we combined, for the first time, AMS analysis with positron emission tomography (PET) in order to determine the pharmacokinetic profile of the model drug verapamil in plasma and brain of humans. In order to assess pharmacokinetic dose linearity of verapamil, data were acquired and compared after administration of an intravenous microdose and after an intravenous microdose administered concomitantly with an oral therapeutic dose. Methods: Six healthy male subjects received an intravenous microdose [0.05 mg] (period 1) and an intravenous microdose administered concomitantly with an oral therapeutic dose [80 mg] of verapamil (period 2) in a randomized, crossover, two-period study design. The intravenous dose was a mixture of (R S)-[
Background
In microdose studies, the pharmacokinetics of a drug are assessed after administration of a dose up to 100 mg in humans. [1, 2] Safety and toxicology testing is reduced for conducting microdose studies, compared to conventional firstin-human (phase I) studies, so that pharmacokinetic properties of drug candidates or drug-drug interactions can be studied at lower cost and earlier along the drug development pathway. [3] The issue of dose linearity is often discussed as a limitation of the microdosing concept, as there is concern that pharmacokinetic data determined after the administration of a microdose might fail to predict pharmacokinetic data of the drug observed at therapeutic doses. [4] However, previous human microdose studies have shown that for many drugs, microdosing can predict human pharmacokinetics at clinically relevant doses. [5] [6] [7] [8] In a comprehensive microdosing review reporting on a total of 18 drugs with different pharmacokinetic properties, [9] 15 drugs demonstrated linear or near-to-linear pharmacokinetics at a microdose and a therapeutic dose in either animals or humans.
The feasibility of performing clinical microdose studies critically depends on the availability of sensitive analytical methods that are capable of detecting minute drug amounts in plasma and tissue samples. [10] A commonly employed method is accelerator mass spectrometry (AMS), an ultrasensitive isotope ratio technique, which relies on the use of carbon-14 ( 14 C)-labelled drugs. In a typical AMS microdosing study, 14 Clabelled drug is administered to human subjects and the drug's plasma concentration is determined by separation of unchanged drug by liquid chromatography followed by AMS analysis, which has a potential sensitivity in the low femtomolar range. [11, 12] A limitation of AMS microdosing is that it mainly provides information on drug distribution to the central blood compartment. This is of limited value as most drugs exert their pharmacological effect in tissue and drug pharmacokinetics in blood may be a poor predictor of drug tissue distribution. [13] The non-invasive nuclear imaging technique positron emission tomography (PET) has been used to study tissue distribution and pharmacokinetics of drugs labelled with positron-emitting radionuclides, such as carbon-11 ( 11 C) or fluorine-18 ( 18 F). [14, 15] For PET imaging, drugs labelled at high specific activity are commonly used, so that the mass of unlabelled drug associated with a PET tracer is usually low enough to satisfy the definition of a microdose. On the other hand, it is difficult to derive standard plasma pharmacokinetic parameters of a drug in PET microdosing studies, due to the short radioactive halflives of positron-emitting radionuclides ( In the present pilot study we combined AMS and PET analysis, for the first time, in order to obtain plasma and brain pharmacokinetics in the same subjects, after administration of a mixture of (R S)-[ ]verapamil in a human microdose study. The calcium channel antagonist verapamil was used as a model drug, because it is a commonly prescribed drug with a well established safety profile, which can be straightforwardly labelled with 11 C and 14 C. In order to assess pharmacokinetic dose linearity of verapamil in plasma and brain, data were acquired and compared after administration of an intravenous microdose (period 1) and after an intravenous microdose administered concomitantly with an oral therapeutic dose (period 2). The intravenous dose was a mixture of (R S)-[ 
Methods
The study was conducted as an open-label, randomized, two-period, crossover, single-intravenous infusion microdose and single-oral therapeutic dose pilot clinical study. The study was conducted in seven healthy male subjects with a mean (-SD) age of 27 -4 years and a mean (-SD) bodyweight of 81 -8 kg. The study was conducted as a pilot study, so no a priori sample size calculation was done. Intake of any medication with known interference with cytochrome P450 (CYP) enzymes or P-glycoprotein (P-gp; ABCB1) within 2 weeks before the start of the study led to study exclusion.
The clinical trial was performed as a collaborative study at the Department of Clinical Pharmacology at the Medical University of Vienna (Vienna, Austria) and at Xceleron Ltd (York, UK). The clinical phase of the study, the collection of blood samples as well as interpretation of all PET data were performed at the Medical University of Vienna, whereas AMS analysis was conducted at Xceleron Ltd.
The study protocol (including issues related to radiation exposure of study subjects) was approved by the ethics committee of the Medical University of Vienna and the Vienna General Hospital-AKH and was performed in accordance with the Declaration of Helsinki (1964) in the revised version of 2000 (Edinburgh), the Guidelines of the International Conference of Harmonization, the Good Clinical Practice Guidelines and the Austrian drug law (Arzneimittelgesetz). All subjects were given a detailed description of the study and their written consent was obtained prior to the enrolment in the study.
Positron Emission Tomography (PET) Imaging and Experimental Procedures
Each study subject underwent two PET scans of 60 minutes duration on two separate study days, separated by a wash-out period of 14-18 days. On one study day, subjects received a microdose (0.05 mg), containing tracer amounts of (R S)-[ 14 C]verapamil and (R)- [ 11 C]verapamil at the beginning of the PET scan (period 1). On the other study day (period 2), subjects were first administered one oral therapeutic dose (80 mg) of racaemic unlabelled verapamil (Isoptin Ò , 80 mg, Abbott, Vienna, Austria). Two hours later (i.e. at the estimated time to reach the maximum concentration (t max ) of verapamil in plasma after oral administration [16] ) the subjects received a microdose (0.05 mg) of (R S)-[
14 C]verapamil and (R)-[ 11 C] verapamil, at the beginning of the PET scan. Subjects underwent period 1 and 2 in a randomized order.
Prior to PET imaging, one venous catheter was placed in a cubital vein of one arm for radiotracer infusion. An arterial catheter was placed in the radial artery of the same arm for arterial blood sampling. A second venous catheter was placed on the other arm for venous blood sampling from 0 to 24 hours after radiotracer injection. For PET imaging, each subject was positioned supine on the imaging bed of the PET camera with the head in a fixing device in order to avoid movement artifacts. PET images were acquired with an Advance PET scanner (General Electrics Medical Systems, Wukesha, WI, USA) run in 3D mode with a transversal field of view (FOV) of 55 cm, an axial FOV of 15 cm and an axial slice thickness of 4.25 mm. In order to correct for tissue attenuation of photons a transmission scan of 5 minutes' duration using two 400 MBq germanium-68 ( 68 Ge) pin sources was recorded prior to radiotracer injection.
At the start of each PET scan, study medication was intravenously injected over 20 seconds. Dynamic PET imaging and arterial blood sampling were started at the time of injection. The following frame sequence was used for PET imaging: 1 · 15 seconds, 3 · 5 seconds, 3 · 10 seconds, 2 · 30 seconds, 3 · 60 seconds, 2 · 150 seconds, 2 · 300 seconds, 4 · 600 seconds. During both scans arterial blood samples were manually drawn into heparinized tubes at intervals of 7 seconds during the first 3 minutes after radiotracer injection and subsequently at 3.5, 5, 10, 20, 30, 40 and 60 minutes after radiotracer injection. Plasma was obtained by centrifugation (3000 · g for 10 minutes at room temperature) and immediately further processed as described below (blood and metabolite analysis). C]methyl triflate with a radiochemical purity >98% and a specific activity at the end of synthesis >20 GBq mmol. [17] Racaemic [ Prior to intravenous injection, one aliquot (0.4 mL) was removed from each dose preparation for determining the concentrations of (R)-and (S)-verapamil by chiral high-performance liquid chromatography (HPLC) as described previously [18] and for determining the administered 14 C amount by liquid scintillation counting. For intravenous injection, the final volume of each dose preparation was adjusted to 10 mL with physiological saline solution. The injected radioactivity of (R S)-[ 
PET Data Analysis
Reconstruction of the PET data was performed by means of iterative reconstruction using the ordered subsets-expectation maximization method with 28 subsets and 2 iterations. The loop filter (Gaussian) was set to a full width at half maximum (FWHM) of 4.3 mm, and a post-filtering algorithm of 6.00 mm FWHM was applied. Attenuation correction was performed using the manufacturer's segmentation algorithm for transmission data. T1-weighted MRI scans had been recorded within 1 month before the PET scan. MRI and PET data were processed with PMOD 2.6 (PMOD Technologies, Zurich, Switzerland), Analyze 8.0 (Biomedical Imaging Resource, Mayo Foundation, Rochester, MN, USA) [19] and SPM5 (SPM5, Wellcome Department of Imaging Neuroscience, University College London, London, UK) software [20] as published in detail before. [21] A whole-brain greymatter region of interest was defined by using the Hammersmith n30r83 three-dimensional maximum probability atlas of the human brain. [22] Radioactivity concentrations (kBq g tissue) were converted into mass concentration values (pg equivalents mL) via the specific activity of the radiotracer (i.e. administered 11 Cradioactivity amount divided by the mass of (R)-verapamil contained in the dose preparation). The concentration data were combined to provide concentration-time curves for the whole observation period.
Blood and Metabolite Analysis
Radioactivity counts in aliquots of arterial blood and plasma were measured with a Packard Cobra II auto-gamma counter (Packard Instrument Company, Meriden, CT, USA), which had been cross-calibrated with the PET camera. Plasma samples were analysed for radiometabolites of (R)-[ 11 C]verapamil by employing a previously described combined solid-phase extraction (SPE) HPLC assay. [23] The polar radiometabolites of (R)-[ Standard 1-tissue-2-rate constant (1T2K) or 2-tissue-4-rate constant (2T4K) compartment models were fitted to the concentration-time curves of radioactivity in whole-brain grey matter to estimate the rate constants of radioactivity exchange between plasma and brain tissue (K 1 , k 2 , k 3 and k 4 ) as well as the volume of distribution (V T ) as described in detail elsewhere. [21, 24] The first-order rate constants K 1 (mL mL min) and k 2 (min -1 ) describe transport of radioactivity from plasma to the first tissue compartment and back, whereas k 3 (min -1 ) and k 4 (min -1 ) characterize exchange of radioactivity between the first and the second tissue compartment. V T is not identical to the volume of distribution (V d ) in standard pharmacokinetic analysis. For the 2T4K compartment model, V T is given as (1 + k 3 k 4 ) (K 1 k 2 ) and can be considered as an estimate of the brain tissue-plasma partition coefficient of radioactivity at equilibrium. Fits were performed by the method of weighted nonlinear least squares as implemented in the Optimization Toolbox of MATLAB (Mathworks, Natick, MA, USA). Goodness of fit was assessed by visual inspection of observed and predicted concentrations versus time, by the correlation between observed and predicted concentrations, by the randomness of the residuals (runs test), and by estimating parameter uncertainties (variances) from the inverse of the appropriate Fisher information matrix. In order to obtain a model-independent estimate of V T , Logan graphical analysis was applied to the PET and arterial plasma data using MATLAB. [25] The slope V T of the linear part of the Logan plot was estimated by linear regression of the Logan variables. The linear regression was assessed by the magnitude of the squared linear correlation coefficient.
Venous Blood Sampling and Accelerator Mass Spectrometry (AMS) Analysis
Venous blood samples (4 mL) were drawn into heparinized tubes at pre-dose as well as at time points of 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours after radiotracer injection. Plasma was obtained by centrifugation (3000 · g for 10 minutes at room temperature) and stored at -80°C until AMS analysis. AMS analysis of (R)-and (S)-[
14 C]verapamil was performed as described previously. [18] In brief, to each plasma sample an excess and known amount of unlabelled verapamil was added and the samples extracted into solvent. Aliquots of the extracts were injected onto a C18 HPLC system and verapamil collected as a discrete fraction. This verapamil fraction was injected onto a chiral HPLC system and the fractions corresponding to (R)-and (S)-verapamil were collected. The UV peak areas corresponding to (R)-and (S)-verapamil were recorded. Fractions containing verapamil enantiomers were converted to graphite and analysed for 14 C-content by AMS. The mass concentration of verapamil enantiomers in plasma was determined from the 14 C content measured by AMS relative to the UV peak area (used as an internal standard). The accuracy of this assay, as previously reported [18] was assessed using quality control samples and the results were within 3% of the true value (13% and 2% coefficient of variation for (R)-and (S)-verapamil, respectively). The limit of quantification of the assay was 1.95-4.81 pg mL for (R)-verapamil and 1.76-3.34 pg mL for (S)-verapamil. Where measured, the mean concentration data were within 2% of the measured concentration (14% coefficient of variation) over a period of at least 48 hours.
Pharmacokinetic Analysis
Pharmacokinetic analysis of verapamil in plasma was performed using WinNonLin software version 4.1 (Pharsight Corporation, Mountain View, CA, USA) using a noncompartmental model. Input consisted of plasma drug concentrations (in pg mL), recorded times of sample collection (in hours) and doses administered. The following pharmacokinetic parameters were calculated: maximum plasma concentration (C max ), terminal elimination half-life (t ½ ), area under the plasma concentration-time curve (AUC) for the period studied, and AUC from time zero to infinity (AUC 1 ), total clearance (CL), volume of distribution (V d ) and volume of distribution at steady state (V ss ).
Statistical Analysis
All statistical analysis was performed using the STATISTI-CA software package (release 6.1, StatSoft, Inc., Tulsa, OK, USA). Model parameters of (R)-[
11 C]verapamil in brain (K 1 , k 2 , k 3 , k 4 , V T ) and plasma pharmacokinetic parameters of verapamil for the two periods were compared using the Wilcoxon matched pairs test. A p level of <0.05 was regarded as significant.
Results
Six subjects completed both study periods and one subject completed only period 2. Isoptin Ò at a therapeutic dose (80 mg) was well tolerated without occurrence of severe or serious adverse events. Mild adverse events, possibly related to administration of the study medication, were headache in two subjects and dizziness in one subject. Figure 1a shows mean concentration-time curves of total 11 C-radioactivity and (R)-[
11 C]verapamil in arterial plasma over 60 minutes following administration of an intravenous microdose (period 1) and an intravenous microdose administered concomitantly with an oral therapeutic dose of verapamil (period 2). There was no significant difference between the AUC of the fractions of polar and lipophilic radiometabolites of (R)- There was no statistically significant difference in any of the pharmacokinetic parameters for (R)-verapamil or (S)-verapamil for period 1 and period 2, respectively, except for V ss of (R)-verapamil, which was smaller for period 2. On the other hand, all pharmacokinetic parameters (except for t ½ ) differed significantly between the (R)-and (S)-enantiomers for the two periods. C max , AUC from 0 to 24 hours (AUC 24 ) and AUC 1 were higher and CL, V d and V ss were lower for the (R)-than for the (S)-enantiomer (table II) . Figure 3 shows concentrations of (R)-verapamil in arterial and venous plasma measured by gamma counting with SPE HPLC correction and by HPLC-AMS, respectively, showing Combined AMS-PET Microdose Studythat both methods to quantify parent in plasma were in reasonably good agreement.
Discussion
The ultrasensitive analytical techniques AMS and PET have both been used in human microdose studies. [9, 15] While AMS is useful for obtaining pharmacokinetics over prolonged periods of time after administration of a 14 C-labelled drug, the main asset of PET is that pharmacokinetic data can be obtained in humans from otherwise inaccessible tissues such as brain, by using drugs labelled with short-lived positron emitters such as 11 C. In the present study, we demonstrated, for the first time, the feasibility of combining AMS and PET analysis in a single clinical microdose study by administering 14 C-and 11 C-labelled verapamil, as a model drug, to human subjects. Because a major question with microdosing is the predictivity of a drug's pharmacokinetics at higher, therapeutic doses, we administered a 14 C-and 11 C-labelled intravenous microdose (period 1) and a 14 C-and 11 C-labelled intravenous microdose administered concomitantly with an unlabelled oral therapeutic dose of verapamil (period 2) in a two-period design, in order to assess the dose linearity of verapamil pharmacokinetics in plasma and brain. It has to be emphasized, however, that such a comparison of a drug's pharmacokinetics at a microdose and a therapeutic dose will not be possible for microdose studies of new drug candidates, because the required safety and toxicology data will usually not be available to allow for administration of therapeutic doses. In the current study however, where an approved drug was investigated, the two-period design allowed for a comparison of the pharmacokinetics to be made at systemic concentrations relevant to both the microdose and therapeutic dose in the same subjects which was considered a more robust approach than using just literature data.
The chosen study design has been used previously to examine the pharmacokinetic linearity of intravenous administered drugs labelled with an isotopic tracer. [5, 12, 26, 27] While the plasma drug concentrations from the intravenous dose alone (period 1) arose entirely from the amount administered intravenously, the plasma drug concentrations from period 2 arose from the sum of the intravenous dose and that absorbed following oral dosing. Plasma concentrations of unlabelled verapamil following oral dosing were not measured in the present study. However, the reported oral bioavailability of verapamil is approximately 20% and the expected C max after a 80 mg oral dose is 130 ng mL and AUC 1 is 450 ng Á h mL. [28] The C max following intravenous microdosing in the current study was 0.31 ng mL and AUC 1 was 0.93 ng Á h mL (total for (R)-and (S)-verapamil) [table II]. The observed pharmacokinetics were therefore shown to be essentially linear over an approximate 420-fold plasma concentration range. By administering the intravenous microdose at the estimated t max of verapamil after oral administration [16] we attempted to approach the elimination phases of the intravenous and the oral drug doses in order to keep the values for the clearance between the two dose routes as equivalent as possible. [27] For AMS analysis [ 14 C]verapamil was administered as a racaemic mixture. Plasma samples were subjected to 2-dimensional reversed-phase followed by chiral HPLC analysis, before AMS analysis, to enable plasma concentrations of (R)-and (S)-verapamil to be measured separately. For PET imaging, how- V T (mL mL) 0.66 -0.12 [4] 0.56 -0.11 [2] V T (Logan; mL mL) 0.66 -0.11 [2] 0.57 -0.11 [1] a Data are presented as mean -SD (period 1: n = 6; period 2: n = 7). The value in square brackets represents the precision of parameter estimates (expressed as their %CV), averaged over the 6 study subjects.
b For all statistical comparisons, data from subject 2, who underwent only period 2, were excluded.
c Rounded to 3 decimal digits.
d A statistically significant difference was observed between the two periods (p < 0.05).
CV = coefficient of variation; K 1 , k 2 , k 3 , k 4 = rate constants for exchange of radioactivity between plasma and first and second tissue compartment; V T = volume of distribution; V T (Logan) = V T estimated with Logan analysis.
ever, the 11 C-labelled (R)-enantiomer of verapamil was used, as PET measures total radioactivity in tissue and does not distinguish between different radiolabelled enantiomers or between unchanged drug and metabolites. (R)-[
11 C]verapamil has been shown to undergo extensive CYP-mediated metabolism, mainly giving rise to polar radiometabolites ([ 11 C]formaldehyde and related species) and the lipophilic N-dealkylation products [ 11 C]D-617 and [ 11 C]D-717. [23, 29] In the present study, it was determined that 42 -8%, 31 -8% and 28 -9% of total plasma radioactivity were in the form of (R)-[ 11 C]verapamil, lipophilic N-dealkylation products, and polar radiometabolites, respectively, at 60 minutes after radiotracer injection. It seems therefore likely that the radiometabolites of (R)-[ 11 C]verapamil contributed to the measured brain PET signal. Hence, the brain tissue pharmacokinetics (figure 1b) and rate constants for plasma-tissue exchange of radioactivity (table I) reported in this study are not wholly representative of parent drug but rather of a mixture of parent drug and its radiometabolites. In the case of (R)-[
11 C]verapamil, however, the major fraction of its radiometabolites ([ 11 C]D-617 and [ 11 C]D-717) can be expected to behave similarly to parent [24] because D-617 and D-717 have been shown, like verapamil itself, to be also transported by P-gp. [30] Although metabolites of [
14 C]verapamil were not directly measured, comparing the concentration-time curves of parent drug (figure 2b and 2c) in plasma with the concentration time-curve of total 14 Cradioactivity (figure 2a), also suggested extensive metabolism of verapamil. [31] At 24 hours after administration of a 14 C-and 11 C-labelled intravenous microdose and a 14 C-and 11 C-labelled intravenous microdose administered concomitantly with an unlabelled oral therapeutic dose of verapamil, the sum of mean (R)-and (S)-[
14 C]verapamil concentrations in plasma represented only about 3% of total 14 C-radioactivity in plasma. It has been previously reported that after intravenous administration of racaemic verapamil, metabolism of (S)-verapamil was higher compared to (R)-verapamil which resulted in higher clearance of the pharmacologically more potent (S)-enantiomer. [32] These results were confirmed in the present study where CL, V d and V ss were higher for (S)-verapamil than for (R)-verapamil, for both periods (table II) . Accordingly, C max , AUC 24 and AUC 1 were lower for (S)-verapamil than for (R)-verapamil (table II) . The value for V ss was approximately 69-76% of V d (table II) , indicating only moderate drug elimination occurs before the terminal phase is reached. In general, the plasma pharmacokinetic parameters of (R)-and (S)-verapamil determined in the present study were in good agreement with those previously reported by Eichelbaum et al. [32] Clearly, for a drug such as a verapamil, which has a t ½ in the range of 6-8 hours, the plasma concentration-time profile of 11 C-labelled parent tracer measured during PET imaging ( figure 1a and figure 3 ) would fail to predict the drug's pharmacokinetic parameters as the drug's elimination phase cannot be captured during the short time course of the PET experiment. [33] For such drugs a combination of PET imaging for assessment of drug tissue distribution with AMS for plasma pharmacokinetic analysis is particularly powerful. Another possible advantage of the AMS-PET combination could be that the rate constants describing exchange of radiolabelled drug between plasma and brain (table I), which are obtained by compartment modelling of the PET data, can be used to predict long-term brain tissue pharmacokinetic data from the venous pharmacokinetic data as measured by AMS analysis as recently described by Bergstro¨m et al. [34] However, this particular approach was not used in the present study due to the possible confounding effect of radiometabolites of (R)-[ 11 C]verapamil, which were also taken up into brain tissue.
An important finding of this study was that verapamil displays to a large degree linear pharmacokinetics in plasma and brain at a microdose and therapeutic dose with nearly superimposable plasma and brain concentration-time curves over the dose range from 0.05 to 80 mg ( figure 1 and 2 ), although it is noted that dose-dependent clearance would be expected at higher doses. [35] This is of particular interest as verapamil is a high-affinity substrate of the efflux transport protein P-gp, which is highly abundant in tissues involved in drug absorption and excretion (kidney, liver, intestines), where it limits absorption and increases excretion of its substrates by active adenosine triphosphate-dependent transport. [36] A moderate degree of non-linearity was observed for (R)-verapamil which had higher C max , AUC 24 and AUC 1 values and lower CL, V d and V ss values for period 2 as compared to period 1 (table II) . This is also in line with the observation that the fraction of polar radiometabolites of (R)-[ 11 C]verapamil was somewhat lower for period 2 than for period 1. Slower metabolism of PET tracers administered at a therapeutic dose as compared to a microdose has also been reported by other investigators. [33] As opposed to standard pharmacokinetic parameters, no statistically significant differences were found for (R)- [ 11 C]verapamil between the two periods for parameters describing exchange of radioactivity between plasma and brain (table I) .
(R)-[ 11 C]verapamil has been used before as a PET tracer to measure P-gp mediated transport at the blood-brain barrier (BBB). [21, 24, 37] Overactivity of P-gp at the BBB has been suggested to be a contributing mechanism to pharmacoresistance in neurological disorders, particularly in medically refractory epilepsy. [38] A promising strategy to overcome drug resistance is treatment with P-gp modulating drugs in combination with neurological drugs. [39] [40] [41] One of the first P-gp modulating drugs employed for overcoming multidrug resistance in cancer was racaemic verapamil, which was then followed by (R)-verapamil. [42] Interestingly, analysis of brain tissue pharmacokinetics of 11 C-radioactivity following (R)- a For all pharmacokinetic parameters except for t ½ a statistically significant difference was observed between the (R)-and (S)-enantiomers (p < 0.05).
c Data are presented as mean -SD (period 1: n = 6; period 2: n = 7).
AUC = area under the plasma concentration-time curve; AUC 24 = AUC from 0 to 24 hours; AUC 1 = AUC from time zero to infinity; CL = total clearance; C max = maximum plasma concentration; t ½ = terminal elimination half-life; V d = volume of distribution; V ss = volume of distribution at steady state.
injection revealed no major differences in brain distribution parameters (V T , K 1 , k 2 ) for the two periods (table I) , which provides strong evidence that therapeutic doses of verapamil are not able to enhance brain uptake of P-gp substrates. Two clinical case reports have recently provided evidence that coadministration of verapamil with antiepileptic therapy might be able to restore treatment response in epilepsy patients. This was at least partly attributed to inhibition of P-gp at the BBB by verapamil, thereby facilitating brain entry of antiepileptic drugs. [43, 44] The verapamil doses used to treat medically refractory epilepsy (1-1.5 mg kg day) [43] were comparable to the single oral verapamil dose given in our study (1 mg kg), which questions whether the observed response in patients was indeed mediated by verapamil-induced cerebral P-gp inhibition.
Conclusion
The presented pharmacokinetic data for verapamil in plasma and brain demonstrate the principle of combining AMS and PET microdosing in a single clinical study. Co-administration of 14 C-labelled drug can be incorporated into standard clinical PET study protocols and thereby allows long-term pharmacokinetic data along with information on drug tissue distribution to be acquired in the same subjects. In contrast to PET microdosing alone, the combination of AMS and PET microdosing allows for an accurate description of a drug's plasma pharmacokinetic parameters. This approach has the potential to maximize the outcomes of a single clinical study in comparison to obtaining the plasma and tissue distribution data of a drug in individual groups of subjects. In addition, by administering an intravenous drug microdose as well as an intravenous microdose over an extravascular therapeutic dose in a two-period design, dose linearity of a drug's pharmacokinetics at a microdose and plasma concentrations relevant to the therapeutic dose can be assessed. The results of this human pilot study suggest that studying drug disposition and pharmacokinetics with AMS and PET offers numerous benefits and may thus be of interest for early clinical drug development. [triangles] after administration of an intravenous microdose (period 1, light grey symbols, n = 6) and after an intravenous microdose administered concomitantly with an oral therapeutic dose of verapamil (period 2, black symbols, n = 7). Note that to facilitate better comparison of datasets, the time axis is not set to the full range of venous plasma sampling (24 hours).
